Skip to main content

Advertisement

Table 8 Overall response rate and PFS in 4 randomized trials comparing gemcitabine to gemcitabine plus other cytotoxic agent

From: Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer

Reference Year n Treatment regimen ORR (%) p Median PFS/TTP (mo) p
Oettle 2005 282 Gemcitabine 7.1 0.004 3.3 0.111
   283 Gemcitabine + Pemetrexed 14.8   3.9  
Rocha Lima 2004 180 Gemcitabine 4.4 < 0.001 3.0 0.352
   180 Gemcitabine + Irinotecan 16.1   3.5  
Stathopoulos 2006 70 Gemcitabine 10 0.387 2.9 0.795
   60 Gemcitabine + Irinotecan 15   2.8  
O'Reilly 2004 174 Gemcitabine 7.1 -- 3.8 0.22
   175 Gemcitabine + Exatecan 8.2   4.1  
  1. ORR = overall response rate; PFS = progression-free survival; TTP = time-to-progression;